Impact of Genetic Polymorphisms in NF- ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients
CONCLUSION: The study findings underscore a significant association between genetic polymorphisms and treatment response outcomes, suggesting their utility in prognostic determinations and clinical outcomes prediction in multiple myeloma patients.PMID:38546066 | DOI:10.31557/APJCP.2024.25.3.829 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - March 28, 2024 Category: Cancer & Oncology Authors: Nidhi Sood Abdoul Hamide Biswajit Dubashi Yadav Nisha Jayanthi Mathaiyan A K Munirajan Prasanth Ganesn Smita Kayal Source Type: research
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study
Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285145. Online ahead of print.ABSTRACTNot available.PMID:38546676 | DOI:10.3324/haematol.2024.285145 (Source: Haematologica)
Source: Haematologica - March 28, 2024 Category: Hematology Authors: Kai-Ni Shen Ya-Juan Gao Long Chang Lu Zhang Xin-Xin Cao Zhuang Tian Yi-Ning Wang Dao-Bin Zhou Jian Li Source Type: research
Impact of Genetic Polymorphisms in NF- ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients
CONCLUSION: The study findings underscore a significant association between genetic polymorphisms and treatment response outcomes, suggesting their utility in prognostic determinations and clinical outcomes prediction in multiple myeloma patients.PMID:38546066 | DOI:10.31557/APJCP.2024.25.3.829 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - March 28, 2024 Category: Cancer & Oncology Authors: Nidhi Sood Abdoul Hamide Biswajit Dubashi Yadav Nisha Jayanthi Mathaiyan A K Munirajan Prasanth Ganesn Smita Kayal Source Type: research
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study
Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285145. Online ahead of print.ABSTRACTNot available.PMID:38546676 | DOI:10.3324/haematol.2024.285145 (Source: Haematologica)
Source: Haematologica - March 28, 2024 Category: Hematology Authors: Kai-Ni Shen Ya-Juan Gao Long Chang Lu Zhang Xin-Xin Cao Zhuang Tian Yi-Ning Wang Dao-Bin Zhou Jian Li Source Type: research
Impact of Genetic Polymorphisms in NF- ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients
CONCLUSION: The study findings underscore a significant association between genetic polymorphisms and treatment response outcomes, suggesting their utility in prognostic determinations and clinical outcomes prediction in multiple myeloma patients.PMID:38546066 | DOI:10.31557/APJCP.2024.25.3.829 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - March 28, 2024 Category: Cancer & Oncology Authors: Nidhi Sood Abdoul Hamide Biswajit Dubashi Yadav Nisha Jayanthi Mathaiyan A K Munirajan Prasanth Ganesn Smita Kayal Source Type: research
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study
Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285145. Online ahead of print.ABSTRACTNot available.PMID:38546676 | DOI:10.3324/haematol.2024.285145 (Source: Haematologica)
Source: Haematologica - March 28, 2024 Category: Hematology Authors: Kai-Ni Shen Ya-Juan Gao Long Chang Lu Zhang Xin-Xin Cao Zhuang Tian Yi-Ning Wang Dao-Bin Zhou Jian Li Source Type: research
Impact of Genetic Polymorphisms in NF- ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients
CONCLUSION: The study findings underscore a significant association between genetic polymorphisms and treatment response outcomes, suggesting their utility in prognostic determinations and clinical outcomes prediction in multiple myeloma patients.PMID:38546066 | DOI:10.31557/APJCP.2024.25.3.829 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - March 28, 2024 Category: Cancer & Oncology Authors: Nidhi Sood Abdoul Hamide Biswajit Dubashi Yadav Nisha Jayanthi Mathaiyan A K Munirajan Prasanth Ganesn Smita Kayal Source Type: research
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study
Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285145. Online ahead of print.ABSTRACTNot available.PMID:38546676 | DOI:10.3324/haematol.2024.285145 (Source: Haematologica)
Source: Haematologica - March 28, 2024 Category: Hematology Authors: Kai-Ni Shen Ya-Juan Gao Long Chang Lu Zhang Xin-Xin Cao Zhuang Tian Yi-Ning Wang Dao-Bin Zhou Jian Li Source Type: research
Impact of Genetic Polymorphisms in NF- ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients
CONCLUSION: The study findings underscore a significant association between genetic polymorphisms and treatment response outcomes, suggesting their utility in prognostic determinations and clinical outcomes prediction in multiple myeloma patients.PMID:38546066 | DOI:10.31557/APJCP.2024.25.3.829 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - March 28, 2024 Category: Cancer & Oncology Authors: Nidhi Sood Abdoul Hamide Biswajit Dubashi Yadav Nisha Jayanthi Mathaiyan A K Munirajan Prasanth Ganesn Smita Kayal Source Type: research
